CY1123365T1 - Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα - Google Patents

Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα

Info

Publication number
CY1123365T1
CY1123365T1 CY20201100912T CY201100912T CY1123365T1 CY 1123365 T1 CY1123365 T1 CY 1123365T1 CY 20201100912 T CY20201100912 T CY 20201100912T CY 201100912 T CY201100912 T CY 201100912T CY 1123365 T1 CY1123365 T1 CY 1123365T1
Authority
CY
Cyprus
Prior art keywords
compounds
beta2
adrenorector
muscarinic receptor
receptor antagonist
Prior art date
Application number
CY20201100912T
Other languages
English (en)
Inventor
Fabio Rancati
Ian Linney
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of CY1123365T1 publication Critical patent/CY1123365T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms

Abstract

Η παρούσα εφεύρεση αφορά σε ενώσεις του γενικού τύπου Ι, οι οποίες δρουν και ως ανταγωνιστές μουσκαρινικού υποδοχέα και ως αγωνιστές βήτα2 αδρενεργικού υποδοχέα, σε μεθόδους για την παρασκευή αυτών, σε συνθέσεις που περιλαμβάνουν αυτές, σε θεραπευτικές χρήσεις και συνδυασμούς με άλλα φαρμακευτικά δραστικά συστατικά.
CY20201100912T 2012-12-06 2020-09-28 Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα CY1123365T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12195891 2012-12-06
EP13811827.8A EP2928889B1 (en) 2012-12-06 2013-12-05 Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
PCT/EP2013/075661 WO2014086924A1 (en) 2012-12-06 2013-12-05 Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity

Publications (1)

Publication Number Publication Date
CY1123365T1 true CY1123365T1 (el) 2021-12-31

Family

ID=47323975

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181100469T CY1120159T1 (el) 2012-12-06 2018-05-03 Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
CY20201100912T CY1123365T1 (el) 2012-12-06 2020-09-28 Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20181100469T CY1120159T1 (el) 2012-12-06 2018-05-03 Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα

Country Status (38)

Country Link
US (2) US8987299B2 (el)
EP (2) EP3345904B1 (el)
JP (1) JP6421989B2 (el)
KR (2) KR102156443B1 (el)
CN (1) CN104822678B (el)
AR (1) AR093825A1 (el)
AU (1) AU2013354043C1 (el)
BR (1) BR112015012730B1 (el)
CA (1) CA2893626C (el)
CL (1) CL2015001483A1 (el)
CO (1) CO7400870A2 (el)
CY (2) CY1120159T1 (el)
DK (2) DK3345904T3 (el)
EA (1) EA030552B1 (el)
ES (2) ES2816210T3 (el)
GE (1) GEP20186839B (el)
HK (1) HK1212989A1 (el)
HR (2) HRP20180915T1 (el)
HU (2) HUE037944T2 (el)
IL (1) IL239182B (el)
LT (2) LT3345904T (el)
MA (1) MA38147B1 (el)
MX (1) MX369311B (el)
NZ (1) NZ708738A (el)
PE (1) PE20151216A1 (el)
PH (1) PH12015501247B1 (el)
PL (2) PL3345904T3 (el)
PT (2) PT2928889T (el)
RS (2) RS57232B1 (el)
SA (1) SA515360514B1 (el)
SG (2) SG11201504318UA (el)
SI (2) SI2928889T1 (el)
TN (1) TN2015000244A1 (el)
TR (1) TR201808698T4 (el)
TW (1) TWI637954B (el)
UA (1) UA118181C2 (el)
WO (1) WO2014086924A1 (el)
ZA (1) ZA201503965B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
BR112015012746A2 (pt) * 2012-12-06 2017-07-11 Chiesi Farm Spa compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
UA118181C2 (uk) * 2012-12-06 2018-12-10 К'Єзі Фармачеутічі С.П.А. Сполуки, які мають активність антагоністів мускаринових рецепторів і агоністів бета-2 адренергічних рецепторів
JP6307091B2 (ja) 2012-12-18 2018-04-04 アルミラル・ソシエダッド・アノニマＡｌｍｉｒａｌｌ， Ｓ．Ａ． β２アドレナリンアゴニスト活性およびＭ３ムスカリンアンタゴニスト活性を有する新規のシクロヘキシルおよびキヌクリジニルカルバメート誘導体
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh) * 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
DK3377108T3 (da) * 2015-11-16 2020-04-20 Chiesi Farm Spa Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2018011090A1 (en) 2016-07-13 2018-01-18 Chiesi Farmaceutici S.P.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CA2994290C (en) 2017-11-06 2024-01-23 Entech Solution As Method and stimulation sleeve for well completion in a subterranean wellbore

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2222128A (en) 1937-01-29 1940-11-19 Pure Oil Co Preparation and separation of aromatic hydrocarbons
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
PL376396A1 (en) 2002-10-11 2005-12-27 Pfizer Inc. Indole derivatives as beta-2 agonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4851937B2 (ja) 2003-11-21 2012-01-11 セラヴァンス， インコーポレーテッド β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物
SI1708992T1 (sl) 2004-01-22 2007-12-31 Pfizer Sulfonamidni derivati za zdravljenje bolezni
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
US7538141B2 (en) 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
PL1730103T3 (pl) 2004-03-23 2010-10-29 Pfizer Pochodne formamidu użyteczne jako adrenoreceptor
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
JP2008510014A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
FR2898640B1 (fr) 2006-03-20 2008-04-25 Siemens Vdo Automotive Sas Procede de transmission d'information relatif au fonctionnement d'un moteur a combustion interne
EP2080523A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist
NZ595850A (en) 2009-04-23 2013-05-31 Theravance Inc DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND Beta2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
JP5379224B2 (ja) * 2009-04-30 2013-12-25 帝人ファーマ株式会社 四級アンモニウム塩化合物
WO2011048409A1 (en) 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
CN103547575B (zh) 2011-06-10 2016-08-17 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
WO2012168359A1 (en) * 2011-06-10 2012-12-13 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
UA118181C2 (uk) * 2012-12-06 2018-12-10 К'Єзі Фармачеутічі С.П.А. Сполуки, які мають активність антагоністів мускаринових рецепторів і агоністів бета-2 адренергічних рецепторів
BR112015012746A2 (pt) * 2012-12-06 2017-07-11 Chiesi Farm Spa compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos

Also Published As

Publication number Publication date
IL239182A0 (en) 2015-07-30
BR112015012730A2 (pt) 2017-07-11
HRP20180915T1 (hr) 2018-07-27
US20140161736A1 (en) 2014-06-12
PL3345904T3 (pl) 2020-12-14
PH12015501247A1 (en) 2015-08-17
AU2013354043B2 (en) 2017-06-15
CL2015001483A1 (es) 2015-10-23
GEP20186839B (en) 2018-04-10
HUE037944T2 (hu) 2018-09-28
MX369311B (es) 2019-11-05
KR102156443B1 (ko) 2020-09-17
MA38147B1 (fr) 2018-09-28
JP6421989B2 (ja) 2018-11-14
CN104822678A (zh) 2015-08-05
CO7400870A2 (es) 2015-09-30
EP2928889A1 (en) 2015-10-14
TW201427976A (zh) 2014-07-16
MA38147A1 (fr) 2018-03-30
CA2893626C (en) 2021-08-24
TWI637954B (zh) 2018-10-11
CN104822678B (zh) 2017-03-08
DK3345904T3 (da) 2020-08-31
NZ708738A (en) 2019-02-22
SG11201504318UA (en) 2015-07-30
RS60864B1 (sr) 2020-11-30
US20150133491A1 (en) 2015-05-14
EA201590873A1 (ru) 2015-09-30
CA2893626A1 (en) 2014-06-12
SA515360514B1 (ar) 2016-08-30
EP3345904B1 (en) 2020-07-29
LT3345904T (lt) 2020-09-25
DK2928889T3 (en) 2018-05-22
KR102240459B1 (ko) 2021-04-16
RS57232B1 (sr) 2018-07-31
SI3345904T1 (sl) 2020-09-30
LT2928889T (lt) 2018-06-11
US8987299B2 (en) 2015-03-24
SG10201704032RA (en) 2017-06-29
KR20150090108A (ko) 2015-08-05
AU2013354043C1 (en) 2017-08-31
SI2928889T1 (en) 2018-05-31
IL239182B (en) 2018-12-31
MX2015006788A (es) 2015-08-05
KR20200027049A (ko) 2020-03-11
TN2015000244A1 (en) 2016-10-03
EP3345904A1 (en) 2018-07-11
PL2928889T3 (pl) 2018-09-28
UA118181C2 (uk) 2018-12-10
ZA201503965B (en) 2016-09-28
HK1212989A1 (zh) 2016-06-24
TR201808698T4 (tr) 2018-07-23
PT2928889T (pt) 2018-05-29
HRP20201435T1 (hr) 2020-11-27
ES2816210T3 (es) 2021-03-31
BR112015012730B1 (pt) 2022-07-05
PT3345904T (pt) 2020-09-07
WO2014086924A1 (en) 2014-06-12
AR093825A1 (es) 2015-06-24
JP2016502557A (ja) 2016-01-28
US9371318B2 (en) 2016-06-21
PH12015501247B1 (en) 2015-08-17
CY1120159T1 (el) 2018-12-12
ES2670686T3 (es) 2018-05-31
HUE051394T2 (hu) 2021-03-01
EP2928889B1 (en) 2018-03-21
EA030552B1 (ru) 2018-08-31
PE20151216A1 (es) 2015-09-08

Similar Documents

Publication Publication Date Title
CY1123365T1 (el) Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CY1116892T1 (el) Ενωσεις οι οποιες εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
EA201401351A1 (ru) Производные бензимидазол-пролина
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
UA111640C2 (uk) ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
BR112015012746A2 (pt) compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
EA201490037A1 (ru) Антагонисты trpv4
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
PH12017501424A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
NI201500080A (es) Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenérgicos y como antagonistas muscarínicos m3.
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
CR20150322A (es) Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenérgicos y como antagonistas muscarínicos m3
EA201501163A1 (ru) Модуляторы рецептора cxcr7
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
EA201001842A1 (ru) Новые соединения, обладающие активностью антагонистов мускариновых рецепторов
EA201590452A1 (ru) СОЛИ СОЕДИНЕНИЯ БЕНЗОТИАЗОЛОНА В КАЧЕСТВЕ АГОНИСТОВ β-2-АДРЕНОРЕЦЕПТОРОВ
UA112586C2 (uk) Похідні бензімідазолпроліну
TN2013000429A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity